US4902514A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Dosage form for administering nilvadipine for treating cardiovascular symptoms
Assignee: Alza Corp
•
Filing: 1988-07-21
•
Granted: 1990-02-20
•
Expires: 2008-07-21
Abstract
Abstract A dosage form is disclosed comprising nilvadipine for administering to a patient in need of cardiovascular therapy.
Inventors
- 👤 Brian L. Barclay
- 👤 Patrick S. L. Wong
- 👤 Jeri D. Wright
- 👤 Jerry D. Childers
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 18:00
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0002; A61K9/0004; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
106 words
A dosage form for administering nilvadipine to a patient, wherein the dosage form comprises: (a) a wall that surrounds; (b) a compartment; (c) a composition in the compartment comprising nilvadipine and a polymer, which composition in the presence of fluid that enters the compartment forms a dispensable formulation; (d) a composition in the compartment comprising a polymer that expands in the presence of fluid that enters the compartment and pushes the dispensable formulation from the dosage form; and, (e) at least one exit passageway in the wall connecting the exterior with the interior of the dosage form for delivering the dispensable nilvadipine formulation to the patient.
Claim 2
Dependent Claim
106 words
A dosage form for administering nilvadipine to a patient, wherein the dosage form comprises: (a) a wall that surrounds; (b) a compartment; (c) a composition in the compartment comprising nilvadipine and a polymer, which composition in the presence of fluid that enters the compartment forms a dispensable formulation; (d) a composition in the compartment comprising a polymer that expands in the presence of fluid that enters the compartment and pushes the dispensable formulation from the dosage form; and, (e) at least one exit passageway in the wall connecting the exterior with the interior of the dosage form for delivering the dispensable nilvadipine formulation to the patient.
Claim 3
Dependent Claim
40 words
The dosage form for administering nilvadipine to a patient according to claim 1, wherein the wall comprises a member selected from the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, and ethyl cellulose.
Claim 4
Dependent Claim
29 words
The dosage form for administering nilvadipine to a patient according to claim 1, wherein the composition comprising nilvadipine comprises a polyethylene oxide having a 100,000 to 300,000 molecular weight.
Claim 5
Dependent Claim
25 words
The dosage form for administering nilvadipine to a patient according to claim 1, wherein the polymer that expands has a 2,000,000 to 5,000,000 molecular weight.
Claim 6
Dependent Claim
26 words
The dosage form for administering nilvadipine to a patient according to claim 1, wherein the dosage form comprises from 3 mg to 75 mg of nilvadipine.
Claim 7
Dependent Claim
48 words
A dosage form for administering nilvadipine to a patient, wherein the dosage form comprises: a nilvadipine composition that weighs about 198 mg and comprises 10 wt % nilvadipine, 84.50 wt % polyethylene oxide comprising a 200,000 molecular weight, and 5.00 wt % hydroxypropylmethylcellulose comprising a 11,200 molecular weight.
Claim 8
Dependent Claim
48 words
A dosage form for administering nilvadipine to a patient, wherein the dosage form comprises: a nilvadipine composition that weighs about 198 mg and comprises 10 wt % nilvadipine, 84.50 wt % polyethylene oxide comprising a 200,000 molecular weight, and 5.00 wt % hydroxypropylmethylcellulose comprising a 11,200 molecular weight.
Claim 9
Dependent Claim
52 words
A dosage form for administering nilvadipine to a patient, wherein the dosage form comprises: a nilvadipine composition that weighs 99 mg and comprises 10.00 wt % nilvadipine, 84.50 wt % polyethylene oxide comprising a 200,000 molecular weight, 5.00 wt % hydroxypropylmethylcellulose comprising a 11,200 molecular weight, and 0.50 wt % magnesium stearate.
Claim 10
Dependent Claim
52 words
A dosage form for administering nilvadipine to a patient, wherein the dosage form comprises: a nilvadipine composition that weighs 99 mg and comprises 10.00 wt % nilvadipine, 84.50 wt % polyethylene oxide comprising a 200,000 molecular weight, 5.00 wt % hydroxypropylmethylcellulose comprising a 11,200 molecular weight, and 0.50 wt % magnesium stearate.
Claim 11
Dependent Claim
46 words
A dosage form for administering nilvadipine to a patient, wherein the dosage form comprises: a nilvadipine composition that weight 198 mg and comprises 10 wt % nilvadipine, 63.5 wt % hydroxypropylcellulose comprising a 60,000 molecular weight, 26 wt % povidone, and 0.5 wt % magnesium stearate.
Claim 12
Dependent Claim
46 words
A dosage form for administering nilvadipine to a patient, wherein the dosage form comprises: a nilvadipine composition that weight 198 mg and comprises 10 wt % nilvadipine, 63.5 wt % hydroxypropylcellulose comprising a 60,000 molecular weight, 26 wt % povidone, and 0.5 wt % magnesium stearate.
Claim 13
Dependent Claim
45 words
A dosage form for administering nilvadipine to a patient, wherein the dosage form comprises: a nilvadipine composition that weighs 99 mg and comprises 10 wt % nilvadipine, 63.5 wt % hydroxypropylcellulose comprising a 60,000 molecular weight, 26 wt % povidone, and the balance magnesium stearate.
Claim 14
Dependent Claim
45 words
A dosage form for administering nilvadipine to a patient, wherein the dosage form comprises: a nilvadipine composition that weighs 99 mg and comprises 10 wt % nilvadipine, 63.5 wt % hydroxypropylcellulose comprising a 60,000 molecular weight, 26 wt % povidone, and the balance magnesium stearate.
References Cited (Backward Citations)
US2845770A
Cited
US3916899A
Cited
US4177256A
Cited
US4200098A
Cited
US4285987A
Cited
US4449983A
Cited
US4764379A
Cited
US4820720A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-02-19 | 1993-08-21 | 1994-02-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-02-19 | 1997-08-21 | 1998-02-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-02-19 | 2001-08-21 | 2002-02-20 | $7700.00 | Window Closed / Lapsed |